Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Antimicrobial activity of flavonoids

T.P. Tim Cushnie, Andrew J. Lamb*

School of Pharmacy, The Robert Gordon University, Schoolhill, Aberdeen AB10 1FR, UK

Abstract

Flavonoids are ubiquitous in photosynthesising cells and are commonly found in fruit, vegetables, nuts, seeds, stems, flowers, tea, wine, propolis and honey. For centuries, preparations containing these compounds as the principal physiologically active constituents have been used to treat human diseases. Increasingly, this class of natural products is becoming the subject of anti-infective research, and many groups have isolated and identified the structures of flavonoids possessing antifungal, antiviral and antibacterial activity. Moreover, several groups have demonstrated synergy between active flavonoids as well as between flavonoids and existing chemotherapeutics. Reports of activity in the field of antibacterial flavonoid research are widely conflicting, probably owing to inter- and intra-assay variation in susceptibility testing. However, several high-quality investigations have examined the relationship between flavonoid structure and antibacterial activity and these are in close agreement. In addition, numerous research groups have sought to elucidate the antibacterial mechanisms of action of selected flavonoids. The activity of quercetin, for example, has been at least partially attributed to inhibition of DNA gyrase. It has also been proposed that sophorflavone G and (-)-epigallocatechin gallate inhibit cytoplasmic membrane function, and that licochalcones A and C inhibit energy metabolism. Other flavonoids whose mechanisms of action have been investigated include robinetin, myricetin, apigenin, rutin, galangin, 2,4,2′-trihydroxy-5′-methylchalcone and lonchocarpol A. These compounds represent novel leads, and future studies may allow the development of a pharmacologically acceptable antimicrobial agent or class of agents.

© 2005 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Keywords: Flavonoids; Antifungal; Antiviral; Antibacterial; Structure–activity; Mechanism of action

1. Introduction

Resistance to antimicrobial agents has become an increasingly important and pressing global problem. Of the 2 million people who acquire bacterial infections in US hospitals each year, 70% of cases now involve strains that are resistant to at least one drug [1]. A major cause for concern in the UK is methicillin-resistant Staphylococcus aureus (MRSA), which was at low levels a decade ago but now accounts for ca. 50% of all S. aureus isolates [2]. Substantial investment and research in the field of anti-infectives are now desperately needed if a public health crisis is to be averted.

Structural modification of antimicrobial drugs to which resistance has developed has proven to be an effective means of extending the lifespan of antimicrobial agents such as the azoles [3], antiviral agents such as the non-nucleoside reverse transcriptase inhibitors [4], and various antibacterial agents including β-lactams and quinolones [5]. It is not surprising then, that in response to antimicrobial resistance, major pharmaceutical companies have tended to concentrate their efforts on improving antimicrobial agents in established classes [6]. However, with the portfolio of chemotherapeutics currently available, it has been acknowledged that researchers are getting close to the end game in terms of parent structure alterations. A call has therefore been made for the development of new classes of drug that work on different target sites to those in current use [7,8].

Rational drug design does not always yield effective antimicrobials. In the past, potent enzyme inhibitors have been successfully designed and synthesised but they had only modest antibacterial activity, probably owing to the complex issue of drug uptake by cells. Broad empirical screening of chemical entities for antimicrobial activity represents an alternative strategy for the development of novel drugs. Natural products have been a particularly rich source of anti-infective agents, yielding, for example, the penicillins in 1940, the tetracyclines in 1948 and the glycopeptides in...
2. Flavonoids: occurrence, functions, structure and nomenclature

Flavonoids are ubiquitous in photosynthesising cells and therefore occur widely in the plant kingdom [10]. They are found in fruit, vegetables, nuts, seeds, stems and flowers as well as tea, wine [11], propolis and honey [12], and represent a common constituent of the human diet [13]. In the US, the daily dietary intake of mixed flavonoids is estimated to be in the range 500–1000 mg, but this figure can be as high as several grams for people supplementing their diets with flavonoids or flavonoid-containing herbal preparations [14].

The function of flavonoids in flowers is to provide colours attractive to plant pollinators [11,15]. In leaves, these compounds are increasingly believed to promote physiological survival of the plant, protecting it from, for example, fungal pathogens and UV-B radiation [13,15]. In addition, flavonoids are involved in photosensitisation, energy transfer, the actions of plant growth hormones and growth regulators, control of respiration and photosynthesis, morphogenesis and sex determination [11,13].

The basic structural feature of flavonoid compounds is the 2-phenyl-benzo[H]pyrane or flavane nucleus, which consists of two benzene rings (A and B) linked through a heterocyclic pyrane ring (C) (Fig. 1) [16]. Flavonoids can be classified according to biosynthetic origin. Some classes, for example chalcones, flavanones, flavan-3-ols and flavan-3,4-diols, are both intermediates in biosynthesis as well as end products that can accumulate in plant tissues. Other classes are only known as end products of biosynthesis, for example anthocyanidins, proanthocyanidins, flavones and flavonoids. Two additional classes of flavonoids are those in which the 2-phenyl side chain of flavanone isomerises to the 3 position, giving rise to isoflavones and related isoflavonoids. The neoflavonoid is formed through further isomerisation to the 4 position [13]. Structures of the major classes of flavonoids are given in Fig. 2. The structures of specific compounds within these classes that possess antimicrobial activity and that are discussed in the present review are summarised in Table 1.

Individual flavonoids may be assigned names in three different ways. Trivial names are employed extensively and sometimes indicate flavonoid class or plant source. For example, names ending in ‘etin’ can denote an anthocyanidin, names ending in ‘inidin’ can denote a flavonol, and compounds tricin and hypolaetin have been extracted from plants belonging to the genera Triticum and Hypolaena. Flavonoids may also be named in a semi-systematic manner based on trivial names such as flavone or chalcone as the parent structure, e.g. 3,5,7,3′-pentahydroxyflavone or 3,3′,4′,5,7-pentahydroxyflavanone. Lastly, flavonoids may be given systematic chemical names, e.g. 3,4-dihydro-2-phenyl-2H-1-benzopyran for flavan, but this method is cumbersome and rarely used [13]. In the present review, trivial names will be used wherever possible.

3. Medicinal properties of flavonoids

Increasingly, flavonoids are becoming the subject of medical research. They have been reported to possess many useful properties, including anti-inflammatory activity, oestrogenic activity, enzyme inhibition, antimicrobial activity [10,13], antiallergic activity, antioxidant activity [11], vascular activity and cytotoxic antitumour activity [15]. For a group of compounds of relatively homogeneous structure, the flavonoids inhibit a perplexing number and variety of eukaryotic enzymes and have a tremendously wide range of activities. In the case of enzyme inhibition, this has been postulated to be due to the interaction of enzymes with different parts of the flavonoid molecule, e.g. carbohydrate, phenyl ring, phenol and benzopyrone ring [10]. Several reviews have been written on the interaction between flavonoids and mammalian cells, including comprehensive articles by Harborne and Williams [15] and Middleton et al. [20]. An extensive review on the biochemistry and medical significance of flavonoids has also recently been produced by Havsteen [21].

4. History of flavonoid use in antimicrobial treatment

For centuries, preparations that contain flavonoids as the principal physiologically active constituents have been used by physicians and lay healers in attempts to treat human diseases [10]. For example, the plant Eucalyptus minute (containing quercetagetin-7-arabinosyl-galactoside) has been used extensively in Argentine folk medicine to treat infectious disease [22]. The healing properties of propolis (or ‘tzori’ in Hebrew) are referred to throughout the Old Testament [23], and this balm was prescribed by Hippocrates (460–377 BC) in Ancient Greece for the treatment of sores and ulcers [24].
Fig. 2. The skeleton structures of the main classes of flavonoids: aurones [17,18], isoflavones [10], chalcones [13,19], flavanones [10,13], flavones [10], flavonols [10], flavan-3-ols [13], anthocyanidins [13,20], flavan-3-ols [10,13], proanthocyanidins (occur as dimers, trimers, tetramers and pentamers, $R=0$, 1, 2 or 3 flavan-3-ol structures) [13], flavans [13], flavan-3,4-diols [13] and dihydrochalcones [13].
Table 1
A summary of the structures of antimicrobial flavonoids discussed within the present review article (compiled from The Handbook of Natural Flavonoids [13] and individual research papers)

| Compound | Substituents at carbon position |
|----------|--------------------------------|
|          | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 0 |
| Flavones and their glycosides | | | | | | | | | |
| Acacetin | – | – | – | OH | – | OH | – | – | – | OCH3 | – |
| Apigenin | – | – | – | OH | – | OH | – | – | – | OH | – |
| Biscaritin | – | – | – | OH | OH | OH | – | – | – | – | – |
| Biscaritin | – | – | – | OH | OH | OH | – | – | – | – | – |
| Chrysanthemum | – | – | – | OH | – | OH | – | – | – | – | – |
| Gardenia A (demethylated) | – | – | – | OH | OH | OH | – | – | – | – | – |
| Genkwanin | – | – | – | OH | – | OCH3 | – | – | – | – | – |
| Luteolin | – | – | – | OH | – | OH | – | – | – | OH | – |
| Luteolin 7-glucoside | – | – | – | OH | OH2 | – | – | – | OH | – | – |
| 7,8-Dihydroxyflavone | – | – | – | – | – | OH | OH | – | – | – | – |
| 5,5′-Dihydroxy-8,2′,4′-trimethoxyflavone | – | – | – | OH | – | OCH3 | – | – | – | – | – |
| 5-Hydroxy-7,4′-dimethoxyflavone | – | – | – | OH | OH | OCH3 | – | – | – | – | – |
| 5,7,4′-Trihydroxy-3′,5′-dimethoxyflavone | – | – | – | OH | – | – | CH3 | OH | CH3 | – | – |
| 6,7,4′-Trihydroxy-5′-dimethoxyflavone | – | – | – | OH | OH | – | – | – | – | – | – |
| Isoflavones | | | | | | | | | |
| 6,8-Diprenylgenistein | – | – | – | OH | R3 | OH | R3 | – | – | OH | – |
| Sophoraflavone A | – | – | – | OH | – | OH | – | * | * | OH | – |
| Flavonols and their glycosides | | | | | | | | | |
| Galangin | – | OH | – | OH | – | OH | – | – | – | – | – |
| Kaepphal | – | OH | – | OH | – | OH | – | – | – | – | – |
| 3-O-methylquercetin | – | OCH3 | – | OH | – | OH | – | – | – | OH | – |
| Morin | – | OH | – | – | – | OH | – | OH | – | OH | – |
| Myricetin | – | OH | – | OH | – | OH | – | OH | – | OH | – |
| Quercetin | – | OH | – | OH | OH | OH | – | – | – | – | – |
| Quercetin-3-0(2′-galloyl)-9-0-glucoside | – | – | – | OH | – | OCH3 | – | – | – | – | – |
| Quercetin-3-0(2′-galloyl)-9-0-tannate | – | – | – | OH | – | OH | – | – | – | – | – |
| Quercetin-3-0(2′-galloyl)-9-0-tannate | – | – | – | OH | – | OH | – | – | – | – | – |
| 3,2′-Dihydroxyflavone | – | OH | – | – | – | OH | OH | – | – | OH | – |
| 3′,7′,3′-Tetrahydroxyflavone | – | – | – | OH | OCH3 | – | – | – | – | – | – |
| Flavan-3-ols | | | | | | | | | |
| Catechin | – | OH | OH | – | OH | – | OH | – | OH | – | OH |
| Epicatechin gallate | – | R8 | OH | OH | – | OH | – | OH | – | OH | – |
| Epigallocatechin | – | OH | OH | OH | OH | OH | – | – | – | – | – |
| Epigallocatechin gallate | – | R8 | OH | OH | OH | OH | OH | OH | – | – | – |
| 3-O-octanoyl-(+)-epicatechin | – | R9 | OH | OH | OH | OH | OH | OH | – | – | – |
| 3-O-octanoyl-(−)-epicatechin | – | R9 | OH | OH | OH | OH | OH | OH | – | – | – |
| Flavanones and their glycosides | | | | | | | | | |
| Lonchocarpol A | – | – | – | OH | R3 | OH | R3 | – | – | OH | – |
| Naringenin | – | – | – | OH | OH | OH | – | – | – | OH | – |
| Naringin | – | – | – | OH | OH | OH | – | – | – | OH | – |
| Pinocembrin | – | – | – | OH | OH | OH | – | – | – | – | – |
| Pinocembrin | – | – | – | OH | OH | OH | – | – | – | – | – |
| Poncirin | – | – | – | OH | OH | – | – | – | – | – | – |
| Sophoraflavone G | – | – | – | OH | OH | OH | R10 | OH | OH | – | – |
| Sophoraflavone G | – | – | – | OH | OH | OH | R10 | OH | OH | – | – |
| 3-Methylsoumiflavone | – | CH3 | – | – | – | – | – | – | – | – | – |
| 5,7,4′-Trihydroxy-8-methyl-6-(3-methyl-[2-| – | – | – | OH | R3 | OH | CH3 | – | – | OH | – |
| Flavones and their glycosides | | | | | | | | | |
| Licorice | – | R11 | OH | – | OCH3 | – | – | – | – | OH | – |
| Licorice | – | – | – | OH | R3 | OCH3 | – | – | – | – | – |
| Licorice | – | – | – | OH | R3 | OCH3 | – | – | – | – | – |
| Licorice | – | – | – | OH | R3 | OCH3 | – | – | – | – | – |
| 2,4,2-Trihydroxychalcone | OH | OH | – | – | – | – | – | – | – | – | – |
| 2,4,2-Trihydroxy-3′-methylchalcone | OH | OH | CH3 | – | – | – | – | – | – | – | – |
has been identified as *5,7,4*'-hardtia texana* prenylated flavanone recently isolated from the shrub posed for use against fungal pathogens of man[15]. An e w spor germination of plant pathogens, they have been pro-

Antifungal activity of flavonoids

- Toxicity of flavonoids

- Antifungal activity of flavonoids

### Table 1 (Continued)

| Compound | Substituents at carbon position: |
|----------|--------------------------------|
|         | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 |
| Flavon-3-4-diols and anthocyanins | -  | O- | -  | -  | -  | -  | Cl | -  | -  |
| Luteolinidin | -  | O- | -  | -  | -  | -  | Cl | -  | -  |
| Pelargonidin chloride | -  | O- | -  | -  | -  | -  | Cl | -  | -  |
| Flavans | -  | O- | -  | -  | -  | -  | Cl | -  | -  |
| 6,6'- Dichroflavan | -  | O- | -  | -  | -  | -  | Cl | -  | -  |
| 7-Hydroxy-3',4'-methyleneoxyflavon | -  | O- | -  | -  | -  | -  | Cl | -  | -  |

R1: Glucuronic acid; R2: glucose; R3: prenyl group; R4: arabinose–galactose; R5: (2′-galloyl)-o-α-arabinopyranosyl; R6: rhamnose; R7: rhamnose–glucose; R8: gallic acid; R9: octanoyl; R10: lavandulyl; R11: 5'-methyl-β-butenone; R12: no substitution; 5′, pyran ring between positions 2′ and 3′; A, O-CH2-O between positions 3′ and 4′.

Note: Hinokiflavone and robustaflavone are biflavonoids (also known as biflavonoids) consisting of two apigenin molecules joined through 1-6-O-β-D and 1-6-β-D linkages, respectively.

The antifungal properties of propolis have been attributed to its high flavonoid content and in particular the presence of the flavonoids galangin and pitocembrin[12,25–27]. Huang- chin (*Scutellaria baicalensis*) is yet another example. This herbal medicine has been used systemically and topically for thousands of years in China for the treatment of periodontal abscesses and infected oral wounds. The flavone baicalein is reported to be largely responsible for this plant’s antimicrobial effects[28].

### 5. Toxicity of flavonoids

It has been suggested that because flavonoids are widely distributed in edible plants and beverages and have previously been used in traditional medicine, they are likely to have minimal toxicity. However, this family of compounds has a diverse range of activities in mammalian cells[14,20] and in vivo confirmation of their side effects would be necessary for a full evaluation of their practical usefulness in the field of modern medicine[29]. Given that the selectivity of flavonoids for eukaryotic enzymes appears to vary from compound to compound[15,20], such a study would need to assess the toxicity of these phytochemicals on an individual basis.

### 6. Antifungal activity of flavonoids

Owing to the widespread ability of flavonoids to inhibit spore germination of plant pathogens, they have been proposed for use against fungal pathogens of man[15]. A new prenylated flavone recently isolated from the shrub *Eisen- hardtia texana* has been identified as 5,7,4'-trihydroxy-8-methyl-6-(3-methyl-[2-butenyl]-25)-flavanone and shown to possess activity against the opportunistic pathogen *Candida albicans* [30]. The flavonoid 7-hydroxy-3',4'- dihydroxy-8,2,4'-dimethoxyflavone and 5,5', dithydroxy-8,2,4'-trimethoxyflavone, together with 5,7,4'-trihydroxy-3',5'-dimethoxyflavone have been reported to exhibit activity against *Aspergillus flavus*[32], a species of fungi that causes invasive disease in immunosuppressed patients[33]. The activity of propolis against dermatophytes and *Candida* spp. has been attributed at least partially to its high flavonoid content[34]. Galangin, a flavonol commonly found in propolis samples[24], has been shown to have inhibitory activity against *Aspergillus tamarii, A. flavus, Cladosporium sphaerospermum, Penicillium digitatum* and *Penicillium italicum* [35].

### 7. Antiviral activity of flavonoids

A recent area of research that is of particular interest is the apparent inhibitory activity of some flavonoids against human immunodeficiency virus (HIV). To date, most if not all investigations have involved work with the pandemic HIV-1 strain and its enzymes. In vitro studies have shown that baicalein inhibits HIV-1 infection and replication. Inhibition of HIV-1 entry into cells expressing CD4 and chemokine co-receptors[36], and antagonism of HIV-1 reverse transcriptase[37] by the flavone O-glycoside have been demonstrated by Li and colleagues. Baicalein[38], robustaflavone and hinokiflavone[39] have also been shown to inhibit HIV-1 reverse transcriptase, as have several catechins, but catechins inhibit other DNA polymerases and their interaction with the HIV-1 enzyme is therefore thought to be non-specific in nature[40]. In addition, it has been demonstrated that several flavonoids, including demethylated gadenin A and 3,2'-dihydroxyflavone, inhibit HIV-1 protease[41]. Robinetin, myricetin, baicalein, quercetagetin[42] and quercetin 3-O-(2′-galloyl)-o-α-arabinopyranoside[43] inhibit HIV-1 integrase, although there are concerns that HIV enzyme inhibi-
tion by quercetatin and myricetin is non-specific[44]. It has also been reported that the flavonoids chrysin, acacetin and apigenin prevent HIV-1 activation via a novel mech-
anism that probably involves inhibition of viral transcription[45]. Interestingly, in a study by Hu and colleagues, chrysin was reported to have the highest therapeutic index of 21 natural and 13 synthetic flavonoids against HIV-1[46].
Several research groups have investigated the relationship between flavonoid structure and inhibitory activity against HIV-1 and its enzymes [39,41,42,44,46]. Furthermore, at least two groups have proposed mechanisms of action for HIV-1 enzyme inhibition [41,42].

Flavonoids also have inhibitory activity against a variety of other viruses. For example, Selway reports that quercetin, morin, rutin, dihydroquercetin, dihydrodiosmetin, leucocyanidin, pelargnidin chloride and catechin possess activity against up to seven types of viruses, including herpes simplex virus (HSV), respiratory syncytial virus, poliovirus and Sindbis virus [11,47]. Proposed antiviral mechanisms of action include inhibition of viral polymerase and binding of viral nucleic acid or viral capsid proteins [47]. In addition to the flavonoids mentioned above, three proanthocyanidins from *Pavetta owariensis* (with structural similarity to proanthocyanidin A2 and cinnamonamm B1 and B2) have been shown to have activity against HSV and coxsackie B virus [48,49]. It has also been demonstrated that two of the flavonoids found in propolis, chrysin and kaempferol, inhibit viral replication of HSV, human coronavirus and rotavirus [50]. More recently, the flavonol galangin has been reported to have significant antiviral activity against HSV and coxsackie B virus [48,49]. It is thought that this is why propolis is more active than its individual compounds [52]. Synergism has also been reported between flavonoids and other antiviral agents. Quercetin, for example, potentiates the effects of 5-ethyl-2′-dichloroflavan. However, despite showing strong in vitro activity, this compound proved unsuccessful in clinical trials [11].

Synergism has also been demonstrated between various combinations of flavones and flavonols. For example, kaempferol and luteolin show synergy against HSV. It has been suggested that this is why propolis is more active than its individual component compounds [52]. Synergism has also been reported between flavonoids and other antiviral agents. Quercetin, for example, potentiates the effects of 5-ethyl-2′-dihydroxyuridine [11] and acyclovir [53] against HSV and pseudorabies infection. Apigenin also enhances the antiviral activity of acyclovir against these viruses [53].

### 8. Antibacterial activity of flavonoids

#### 8.1. Reports of flavonoids possessing antibacterial activity

The antibacterial activity of flavonoids is being increasingly documented. Crude extracts from plants with a history of use in folk medicine have been screened in vitro for antibacterial activity by many research groups. Flavonoid-rich plant extracts from species of *Hypericum* [54], *Capsella* [55] and *Chromolaena* [55] have been reported to possess antibacterial activity. Many other phytochemical preparations with high flavonoid content have also been reported to exhibit antibacterial activity [22,56–63]. Propolis has been analysed on many occasions too, and samples containing high concentrations of flavonoids are frequently reported to show antibacterial activity [12,25–27,50,64].

Many research groups have gone one step further and identified the structure of flavonoids that possess antibacterial activity, or quantified the activity of commercially available flavonoids. Examples of such flavonoids are apigenin [65–73], galangin [35,74–77], pinocembrin [78,79], ponciretin [80,81], genkwanin [86,82], sophorafflanovone G and its derivatives [29,83–85], naringin and naringenin [29,60,86,87], epigallocatechin gallate and its derivatives [74,88–95], luteolin and luteolin 7′-glucoside [69,73,96], quercetin, 3-O-methylquercetin and various quercetin glycosides [60,65,72,87,97–102] and kaempferol and its derivatives [60,65,74,76,87,98,100,103]. Other flavones [32,60,74,104–107], flavone glycosides [86,108,109], isoflavones [110,111], flavonones [29,30,78,79,104,111–114], isoflavonones [115], isoflavans [116], flavonols [74,114,117], flavanon glycosides [86,118–120] and chalcones [79,104,111,121] with antibacterial activity have also been identified.

Some researchers have reported synergy between naturally occurring flavonoids and other antibacterial agents against resistant strains of bacteria. Examples of these include epicatechin gallate [122–125] and sophorafflanovone G [83,84]. At least one group has demonstrated synergy between flavonoids with antibacterial activity [126]. Others have synthetically modified natural flavones and analysed them for antibacterial activity [94,127–131]. For example, Wang and colleagues have complexed 5-hydroxy-7′,4′-dimethoxyflavone with a number of transition metals and shown that this process increases antibacterial activity [130]. Another group reported increased antibacterial activity of 3-methyleneflavonanes when the B ring contained bromine or chlorine substituents [131]. Two research groups have described the use of flavonoids in vivo. In a study by Vijaya and Ananthan, oral administration of either 142.9 mg/kg quercetin or 214.3 mg/kg quercetin protected guinea pigs against an induced *Shigella* infection that killed untreated control animals [132]. More recently, Dasti-dar and co-workers reported that intraperitoneal injection of either 1.58 mg/kg sophoraflavanone A or 3.16 mg/kg 6,8-diprenylgenistenin gave significant protection to mice challenged with *Salmonella typhimurium* [110].

#### 8.2. Discrepancies between reports of flavonoid antibacterial activity

When reports of the antibacterial activity of flavonoids are compared, the results appear widely conflicting (Table 2). For example, it was published that apigenin had no activity against *S. aureus* at concentrations up to 128 μg/mL [72], a separate study in the same year reported that the flavone inhibited the growth of 15 strains of MRSA and 5 sensitive strains of *S. aureus* at concentrations between 3.9 μg/mL.
Table 2

| Strain                      | Khanna et al. (DD) | Miski et al. (DD) | Palacios et al. (DD) | Oksuz et al. (DD) | Oksuz et al. (BMAD) | Ohemeng et al. (BMID) | Bashir et al. (NS) | Aljancic et al. (AWD) | Basile et al. (BMAD) |
|----------------------------|-------------------|-------------------|---------------------|-----------------|---------------------|---------------------|-------------------|---------------------|---------------------|
| Staphylococcus aureus       | ++                | −                 | −                   | −               | +                   | −                   | ++                | +                   | +                   |
| Staphylococcus albus        | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Staphylococcus epidermidis  | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Enterococcus faecalis       | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Bacillus subtilis           | ++                | ++                | +                   | ++              | ++                  | ++                  | ++                | ++                  | ++                  |
| Micrococcus luteus          | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Escherichia coli            | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Pseudomonas aeruginosa      | ++                | ++                | +                   | ++              | ++                  | ++                  | ++                | ++                  | ++                  |
| Proteus vulgaris            | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Proteus mirabilis           | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Klebsiella pneumonia        | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Salmonella typhimurium      | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Enterobacter aerogenes      | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Enterobacter cloacae        | −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |
| Stenotrophomonas maltophilia| −                 | −                 | −                   | −               | −                   | −                   | −                 | −                   | −                   |

and 15.6 μg/mL [73]. From Table 2 it can be seen that such discrepancies could perhaps be attributed on occasion to different assays being used (e.g. [65,70] and [72,73]). Many different assays are employed in flavonoid research, including the agar dilution technique [29], the paper disk diffusion assay [115], the hole-plate diffusion method [22], the cylinder diffusion method [60], the broth microdilution technique [71] and the broth macrodilution technique [134]. In particular, assays relying on diffusion of test flavonoids may not give a reliable quantitative measure of antibacterial activity because a potent antibacterial flavonoid may have a low rate of diffusion [32]. However, it is clear from Table 2 that additional factors are involved in causing these discrepancies because even groups using the same assay are obtaining conflicting results (e.g. [67,96] and [67,72]). Such inconsistencies may be due to variations within each assay. For example, different groups using the agar dilution technique have used different sizes of bacterial inoculum [81,86]. In a report by the National Committee for Clinical Laboratory Standards (NCCLS), inoculum size was considered the single most important variable in susceptibility testing [135]. It should be noted that many groups assaying flavonoid antibacterial activity have not quantified the test bacterial suspension [60,115] and others have not even standardised the size of their unenumerated inocula [35,56,76,90,97]. From the published work it is clear that, in addition to inoculum size, there are many other variable factors for each type of assay. These include volume of broth or agar [90,116], type of broth or agar [86,92], size of wells [56,60], size of paper disks [57,65], strains of a particular bacterial species used [69,72] and incubation period [90,116]. Recently, a set of guidelines was published for standard agar dilution, broth macrodilution and broth microdilution methods [136]. This may help to reduce the number of conflicting reports of flavonoid antibacterial activity in the future. However, it will remain necessary to consider carefully additional variables such as the solvent used to dissolve test flavonoids [116,118]. It has previously been shown that precipitation occurs when selected flavonoids are dissolved in organic solvents and diluted with neutral polar solutions [75]. Precipitation of flavonoids in a minimum inhibitory concentration (MIC) assay is likely to cause diminished contact between bacterial cells and flavonoid molecules and may lead to false negative reports of antibacterial activity. Also, in improperly controlled experiments, flavonoid precipitation could be misinterpreted as bacterial growth and further false negative results may be recorded as a consequence. The structural alteration of flavonoids such as galangin in alkaline solvents is another matter for consideration [75]. If flavonoid salts are formed and these have increased or decreased potency compared with the parent structure, this may lead to false positive/negative reports of antibacterial activity. Other variables worth noting include whether the test flavonoids are obtained from a commercial or natural source [35,74] and which companies [74,75]/natural products [71,72] the compounds are from.
8.3. Structure–activity relationship for antibacterial activity of flavonoids

The diverse range of cell functions affected by flavonoids in eukaryotic systems is well documented [10, 20]. Although there have been comparatively few studies into the mechanisms underlying flavonoid antibacterial activity, information from published literature indicates that different compounds within this class of phytochemicals may target different components and functions of the bacterial cell [137–139]. If this is the case, it is surprising that the small number of groups which have investigated the relationship between flavonoid structure and antibacterial activity (summarised below) have been able to identify common structural features among active compounds. However, it may be that individual antibacterial flavonoids have multiple cellular targets, rather than one specific site of action. Alternatively, these common structural features may simply be necessary for flavonoids to gain proximity to or uptake into the bacterial cell.

Tsuchiya and colleagues sought to establish a structure–activity relationship for flavonoids by isolating a number of differently substituted compounds and determining their MICs against MRSA [29]. Their study indicated that 2,4′- or 2,6′-dihydroxylation of the B ring and 5,7-dihydroxylation of the A ring in the flavone structure was important for anti-MRSA activity. Substitution at the 6 or 8 position with a long chain aliphatic group such as lavandulyl (5-methyl-2-isopropenyl-hex-4-enyl) or geranyl (trans-3,7-dimethyl-2,6-octadienyl) also enhanced activity [29]. Interestingly, a recent report by Stapleton and colleagues demonstrated that substitution with C3 and C5 chains also enhanced the staphylococcal activity of flavonoids belonging to the flavan-3-ol class [94].

Oswa et al. assessed the activity of a number of structurally different flavonoids including flavones, flavanones, isoflavones and isoflavonones based on the paper disk agar diffusion assay [115]. It was shown that 5-hydroxyflavonones and 5-hydroxyisoflavonones with one, two or three additional hydroxyl groups at the 7, 2′ and 4′ positions inhibited the growth of Streptococcus mutans and Streptococcus sobrinus. These results correlate well with those of Tsuchiya and colleagues [29]. It was also reported by Oswa and colleagues that 5-hydroxyflavones and 5-hydroxyisoflavones with additional hydroxyl groups at the 7, 2′ and 4′ positions inhibited the growth of Streptococcus mutans and Streptococcus sobrinus. These results correlate well with those of Tsuchiya and colleagues [29]. It was also reported by Oswa and colleagues that 5-hydroxyflavones and 5-hydroxyisoflavones with additional hydroxyl groups at the 7, 2′ and 4′ positions inhibited the growth of Streptococcus mutans and Streptococcus sobrinus. These results correlate well with those of Tsuchiya and colleagues [29].

As mentioned previously, Ward and colleagues synthesised a number of halogenated derivatives of 3-methylleneflavone [131]. Substitution of the B ring was found to enhance antibacterial activity, with 3′-chloro, 4′-chloro and 4′-bromo analogues each being approximately twice as effective as their parent compound against S. aureus, and four times more active against Enterococcus faecalis. Also, the 2′,4′-dichloro derivative exhibited a four- to eight-fold improvement in activity against S. aureus and a two- to four-fold improvement against E. faecalis. By contrast, 3-methylene-6-bromoflavone was less potent than the parent compound and the authors suggested that halogenation upon antibacterial activity could be properly assessed.

8.4. Nature of flavonoid activity: bacteriostatic or bactericidal?

Several research groups have attempted to determine whether flavonoid activity is bacteriostatic or bactericidal by conducting time–kill studies. In such experiments, epigallocatechin gallate [89], galangin [75] and 3-O-octanoyl- (+)-catechin [94] have been shown to cause a reduction of 1000-fold or more in viable counts of MRSA-YK, S. aureus NCTC6571 and EMRSA-16, respectively. This would immediately appear to suggest that flavonoids are capable of bactericidal activity. However, it has recently been demonstrated that 3-O-octanoyl- (+)-epicatechin induces the formation of pseudomulticellular aggregates both in antibiotic-sensitive and antibiotic-resistant strains of S. aureus [94]. If this phenomenon is induced by other compounds within the flavonoid class (and liposomal studies suggest that this is the case for epigallocatechin gallate [88]), questions are raised regarding the interpretation of results from time–kill studies. It may be that flavonoids are not killing bacterial cells but merely inducing the formation of bacterial aggregates and thereby reducing the number of CFUs in viable counts.
8.5. Antibacterial mechanisms of action of various flavonoids

8.5.1. Inhibition of nucleic acid synthesis

In a study using radioactive precursors, Mori and colleagues showed that DNA synthesis was strongly inhibited by flavonoids in Proteus vulgaris, while RNA synthesis was most affected in S. aureus [138]. Flavonoids exhibiting this activity were robinetin, myricetin and (−)-epigallocatechin. Protein and lipid synthesis were also affected but to a lesser extent. The authors suggested that the B ring of the flavonoids may play a role in intercalation or hydrogen bonding with the stacking of nucleic acid bases and that this may explain the inhibitory action on DNA and RNA synthesis [138].

Ohemeng et al. screened 14 flavonoids of varying structure for inhibitory activity against Escherichia coli DNA gyrase, and for antibacterial activity against Staphylococcus epidermidis, S. aureus, E. coli, S. typhimurium and Stenotrophomonas maltophilia [68]. It was found that E. coli DNA gyrase was inhibited to different extents by seven of the compounds, including quercetin, apigenin and 3,6,7,3′,4′-pentahydroxyflavone. Interestingly, with the exception of 7,8-dihydroxyflavone, enzyme inhibition was limited to those compounds with B-ring hydroxylation [68,141]. The authors proposed that the observed antibacterial activity of the seven flavonoids was due in part to their inhibition of DNA gyrase. However, since the level of antibacterial activity and enzyme inhibition did not always correlate, they also suggested that other mechanisms were involved [68].

More recently, Plaper and colleagues reported that quercetin binds to the GyrB subunit of E. coli DNA gyrase and inhibits the enzyme’s ATPase activity [142]. Enzyme binding was demonstrated by isolating E. coli DNA gyrase and measuring quercetin fluorescence in the presence and absence of the gyrase subunits. The flavonoid-binding site was postulated to overlap with those of ATP and topotecan, since addition of these compounds interfered with quercetin fluorescence. Inhibition of GyrB ATPase activity by quercetin was also demonstrated in a coupled ATPase assay. This research is in agreement with the earlier findings of Ohemeng et al. [68] and supports the suggestion that quercetin’s antibacterial activity against E. coli may be at least partially attributable to inhibition of DNA gyrase.

When screening natural products for type II topoisomerase inhibitors, Bernard and co-workers found that the glycosylated flavonol rutin was very effective [143]. This compound exhibited antibacterial activity against a permeable E. coli strain (a strain into which the envA′ allele had been incorporated [144,145]). Using enzyme assays and a technique known as the SOS chromotest, it was shown that rutin selectively promoted E. coli topoisomerase IV-dependent DNA cleavage, inhibited topoisomerase IV-dependent decatenation activity and induced the SOS response of the E. coli strain. The group suggested that since topoisomerase IV is essential for cell survival, the rutin-induced topoisomerase IV-mediated DNA cleavage leads to an SOS response and growth inhibition of E. coli cells [143].

Within our own laboratory, a 4-quinolone-resistant S. aureus strain was shown to have increased susceptibility to the flavonol galangin compared with other 4-quinolone-sensitive and -resistant strains [146]. Interestingly, this strain possesses a distinct amino acid substitution (serine to proline) at position 410 of the GrlB subunit. This may suggest that topoisomerase IV and the relatively homologous gyrase enzyme are involved in the antibacterial mechanism of action of galangin. Clearly, however, further work with mutant strains and purified enzymes would be necessary before this could be verified.

8.5.2. Inhibition of cytoplasmic membrane function

A research team that had previously found Sophoraflavanone G to have intensive antibacterial activity against MRSA and streptococci [83–85] recently reported attempts to elucidate the mechanism of action of this flavanone [139]. The effect of sophoraflavanone G on membrane fluidity was studied using liposomal model membranes and compared with the less active flavanone naringenin, which lacks 8-lavandulyl and 2′-hydroxy groups. At concentrations corresponding to the MIC values, sophoraflavanone G was shown to increase fluorescence polarisation of the liposomes significantly. These increases indicated an alteration of membrane fluidity in hydrophilic and hydrophobic regions, suggesting that sophoraflavanone G reduced the fluidity of outer and inner layers of membranes. Naringenin also exhibited a membrane effect but at much higher concentrations. This correlation between antibacterial activity and membrane interference was suggested to support the theory that sophoraflavanone G demonstrates antibacterial activity by reducing membrane fluidity of bacterial cells [139].

Another group, Ikigai and colleagues, carried out research on (−)-epigallocatechin gallate, a strongly antibacterial catechin found in green tea. Catechins are a group of flavonoids that appear to have greater activity against Gram-positive bacteria than Gram-negative bacteria [88]. In this study, liposomes were again used as model bacterial membranes, and it was shown that epigallocatechin gallate induced leakage of small molecules from the intraliposomal space. Aggregation was also noted in liposomes treated with the compound. The group therefore concluded that catechins primarily act on and damage bacterial membranes. It was not known how this damage occurred but two theories were put forward. First, catechins may perturb the lipid bilayers by directly penetrating them and disrupting the barrier function. Alternatively, catechins may cause membrane fusion, a process that results in leakage of intramembranous materials and aggregation. Interestingly, the group also demonstrated that leakage induced by epigallocatechin gallate was significantly lower when liposome membranes were prepared containing negatively charged lipids. It was therefore suggested that the low catechin susceptibility of Gram-negative bacteria may be at
least partially attributable to the presence of lipopolysaccha-
ride acting as a barrier [88].

As mentioned previously, Stapleton and colleagues found that substitution with C8 and C10 chains increased the antibac-
terial activity of selected flavan-3-ols (catechins). The group went on to show that cells of an MRSA clinical isolate treated with (−)-epicatechin gallate and 3-O-octanoyl-(+)-catechin, respectively, exhibited moderately and highly increased lev-
els of labelling with the selectively permeable fluorescent
stain propidium iodide. In addition, when S. aureus cells were
grown in the presence of either (−)-epicatechin gallate or 3-
O-octanoyl(−)-epicatechin and examined by transmission
electron microscopy, they were shown to form pseudomulti-
cellular aggregates [94]. This work constitutes a substantial
advance in the development of catechins as antibacterial
agents and lends support to Ligiar’s argument that catechins act on and damage bacterial membranes.

It has also been demonstrated by Sato and colleagues that the chalcone 2,4,2′-trihydroxy-5′-methylchalcone induces
leakage of 260 nm absorbing substances from S. mutans.
This observation generally indicates leakage of intracellular
material such as nucleotide, and the authors suggested that
2,4,2′-trihydroxy-5′-methylchalcone exerts its antibacterial
effect by changing the permeability of the cellular membrane and
damaging membrane function [140].

In addition, the effect of galangin upon cytoplasmic
integrity in S. aureus has been investigated by measuring
loss of internal potassium [147]. When high cell densities
of S. aureus were incubated for 12 h in media containing
50 μg/mL of the flavonol, a 60-fold decrease in the number
of CFUs was noted and cells lost ca. 20% more potassium
than untreated control bacteria. These data strongly suggest
that galangin induces cytoplasmic membrane damage and
potassium leakage. Whether galangin damages the mem-
brane directly, or indirectly as a result of autolysis or cell wall
damage and osmotic lysis, remains to be established however
[147].

In an investigation into the antimicrobial action of propo-
lis, Mirzoeva and colleagues showed that one of its con-
stituent flavonoids, quercetin, caused an increase in perme-
ability of the inner bacterial membrane and a dissipation of
the membrane potential [148]. The electrochemical gradient
of protons across the membrane is essential for bacteria to
maintain capacity for ATP synthesis, membrane transport and
motility. Mirzoeva et al. suggested that the effect of propo-
lis on membrane permeability and membrane potential may
contribute enormously to its overall antibacterial activity and
may decrease the resistance of cells to other antibacterial
agents. It was thought that this might explain the synergistic
effect that occurs between propolis and other antibiotics such
as tetracycline [148] and ampicillin [149]. The group also
demonstrated that the flavonoids quercetin and naringenin
significantly inhibited bacterial motility, providing further
evidence that the proton motive force is disrupted. Bacte-
rrial motility and chemotaxis are thought to be important in
virulence as they guide bacteria to their sites of adherence
and invasion. Mirzoeva et al. suggested that the antimotil-
ity action of propolis components may have an important
role in inhibition of bacterial pathogenesis and the develop-
ment of infection [148]. The cytoplasmic membrane activ-
dity detected for quercetin by Mirzoeva and co-workers may
represent one of the additional mechanisms of antibacterial
action that was suspected to be present among the seven DNA
gyrase-inhibiting flavonoid compounds tested by Ohemeng
and colleagues [68].

8.5.3. Inhibition of energy metabolism

Haraguchi and colleagues recently carried out an investi-
gation into the antibacterial mode of action of two retrochal-
cones (licochalcone A and C) from the roots of Glycyrrhiza
inflata [137]. These flavonoids demonstrated inhibitory activ-
ity against S. aureus and Micrococcus luteus but not against
E. coli, and in preliminary tests licochalcone A inhibited
incorporation of radioactive precursors into macromolecules
(DNA, RNA and protein). The group hypothesised that the
licochalcones may be interfering with energy metabolism
in a similar way to respiratory-inhibiting antibiotics, since
energy is required for active uptake of various metabolites
and for biosynthesis of macromolecules [137]. Interestingly,
the licochalcones were found to inhibit strongly oxygen con-
sumption in M. luteus and S. aureus but not in E. coli, which
correlated well with the observed spectrum of antibacterial
activity. The group further demonstrated that licochalcones
A and C effectively inhibited NADH-cytochrome c reduc-
tase, but not cytochrome c oxidase or NADH-CoQ reductase.

It was therefore suggested that the inhibition site of these
retrochalcones was between CoQ and cytochrome c in the
bacterial respiratory electron transport chain [137].

Merck Research Laboratories recently reported that the
flavonone lonchocarpol A inhibits macromolecular synthesis
in Bacillus megaterium. Using radioactive precursors, it was
demonstrated that RNA, DNA, cell wall and protein synthesis
were all inhibited at concentrations similar to the MIC value
[150]. This may represent another example of a flavonoid that
interferes with energy metabolism.

9. Concluding remarks

With regard to natural products, it is generally accepted
that phytochemicals are less potent anti-infectives than agents
of microbial origin, i.e. antibiotics [48]. However, new classes
of antimicrobial drug are urgently required and the flavonoids
represent a novel set of leads. Future optimisation of these
compounds through structural alteration may allow the devel-
opment of a pharmacologically acceptable antimicrobial
agent or group of agents. Existing structure-activity data
suggest that it might be possible, for example, to prepare
a potent antibacterial flavonone by synthesising a compound
with halogenation of the B ring as well as lavandulyl or ger-
anyl substitution of the A ring. Also, it is worth noting that
the rapid progress which is being made toward elucidation
of flavonoid biosynthetic pathways [151] may soon allow the production of structural analogues of active flavonoids through genetic manipulation. Screening of these analogues might lead to the identification of compounds that are sufficiently potent to be useful as antifungal, antiviral or antibacterial chemotherapeutics. In addition to the structural alteration of weakly active antimicrobial flavonoids, investigation into the mechanisms of action of these compounds is likely to be a productive area of research. Such information may assist in the optimisation of a lead compound's activity, particularly focus for toxicological attention and aid in the anticipation of resistance. Also, characterisation of the interaction between antimicrobial flavonoids and their target sites could potentially allow the design of second-generation inhibitors.

Acknowledgements

The authors are very grateful to Dr Paul Kong and Dr Satyajit Sarker for critiquing preliminary drafts of the manuscript and for advice on flavonoid classification and structure. Thanks are extended to Dr Peter Taylor for insightful comments regarding interpretation of data from time–kill studies with flavonoids. Thanks also to Dr Derek Chapman, Miss Vivienne Hamilton, Dr Bruce Thomson and Mrs Amina Al-Mossawi for their kind support and encouragement.

References

[1] Infectious Diseases Society of America. Statement of the IDSA concerning ‘Bioshield B: Responding to an ever-changing threat’. Alexandria, VA: IDSA; 2004.
[2] Adcock H. Pharmageddon: is it too late to tackle growing resistance to anti-infectives? Pharm J 2002;269:599–600.
[3] Lee J, Pacentzi FJ, Lyakhovetsky AG, Fung HB. Voncomazole. Chin Thor 2003;25:1321-41.
[4] De Clercq E. New developments in anti-HIV chemotherapy. Farnamco 2001;56:3–12.
[5] Poole K. Overcoming antimicrobial resistance by targeting resistance mechanisms. J Pharm Pharmacol 1999;51:283–94.
[6] Taylor PW, Stapleton PD, Paul Luzio J. New ways to treat bacterial infections. Drug Discov. Today 2002;7:1086–91.
[7] Anonymous. The global threat of antibiotic resistance (British Pharmaceutical Conference 2000). Pharm J 2000;265:692–4. 1982;37:864–5.
[8] Kimberlin DW, Whitley RJ. Antiviral resistance: mechanisms, clinical significance, and future implications. J Antimicrob Chemother 1997;50:27–34.
[9] Li BQ, Fu T, Dongyan Y, Mikovits JA, Ruscetti FW, Wang JM. Inhibition of reverse transcriptase activity by a flavonoid compound purified from Chinese herbal medicine. Curr Med Res Dev 1993;3:19–24.
[10] Bosio K, Avanzini C, D’Avolio A, Ozino O, Savoia D. In vitro activity of propolis against Streptococcus pyogenes. Lett Appl Microbiol 2000;31:174–7.
[11] Delorme E, Abdi El Hady FK, Abdi Allah FA. Chemical composition and antimicrobial activity of European propolis. Z Naturforsch [C] 2000;55:70–5.
[12] Tsuchiya H, Sato M, Miyazaki T, et al. Comparative study on the antibacterial activity of phytochemical flavanones against methicillin-resistant Staphylococcus aureus. J Ethnopharmacol 1996;50:27–34.
[13] Wachter GA, Hoffmann JJ, Furbacher T, Blake ME, Timmermann BN. Activity of plant flavonoids against antibiotic-resistant bacteria. Phytother Res 2001;15:39–43.
[14] Skibola CF, Smith MT. Potential health impacts of excessive flavonoid intake. Free Radic Res Med 2000;29:375-83.
[15] Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000;55:481–504.
[16] Brown JP. A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat Res 1986;175:241–77.
[17] Muzzig T, Cull Y, Wojcik R. Comparison of binding interactions of dibromo-flavonoids with transferrin. Acta Biochim Pol 2001;48:885–92.
[18] Vilenius D, Marlin B, Bar N. Application of microwave in organic synthesis: dry synthesis of 2-aryl-6H-1,2,3-naphtho-benzofuranones. Molecules 1999;4:38–93.
[19] Xu HX, Lee SF. Activity of plant flavonoids against antibiotic-resistant bacteria. Phytother Res 2002;16:39–43.

T.P.T. Cushnie, A.J. Lamb / International Journal of Antimicrobial Agents 26 (2005) 343–356
Lin YM, Anderson H, Flavin MT, et al. In vitro anti-HIV activity of biflavonoids isolated from Blue succedaneum and Guainia barbata. J Nat Prod 1997;60:962–7.

Moore PS, Piza C. Observations on the inhibition of HIV-1 reverse transcriptase by catechins. Biochim J 1992;288:717–8.

Brinkworth RI, Steemers MJ, Faizie DP. Flavones are inhibitors of HIV-1 protease. Biochem Biophys Res Commun 1992;188:631–7.

Fesen MR, Pommerie Y, Leutarze F, Hiroshi S, Yang J, Kohn KW. Inhibition of HIV-1 integrase by flavonoids, caffeic acid and their esters (CAPE) and related compounds. Biochem Pharmacol 1994;48:595–608.

Kim HS, Woo EB, Shim GU, Park H. A new flavon glycoside gallate ester from Acer pseudosinense and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J Nat Prod 1998;61:145–4.

Oro K, Nakahara H, Fukishima M, Chermarn JC, Burrow-Simons F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur J Biochem 1990;190:469–76.

Crithfield JW, Butera ST, Folks TM. Inhibition of HIV activation in laser injected cells by flavonoid compounds. AIDS Res Hum Retroviruses 1996;12:39–46.

Hao CQ, Chen K, Shi Q, Kiliakoske RE, Cheng YC, Lee KH. Anti-AIDS agents. 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids. J Nat Prod 1994;57:42–51.

Selvey JWT. Antiviral activity of flavones and flavonoids. In: Cody V, Malidoni E, Harborne JB, editors. Plant flavonoids in biology and medicine: biochemical, pharmacological, and structure-activity relationships. New York, NY: Alan R. Liss, Inc.; 1986.

Yamada H. Natural products of commercial potential as medicines. Jpn J Crude Drug Res 1986;24:147–53.

Balde AM, Van Hoof L, Pietro LA, Vanden Bergh DA, Vleminck AJ. Plant antiviral agents. VII. Antiviral and antibacterial proanthocyanidins from the bark of Passiflora edulis. Phytother Res 1990;4:182–8.

Cheng PC, Wong G. Honey bee propolis: prospects in medicine. Bee World 1996;77:8–13.

Meyer JJ, Alfordyan AJ, Taylor MB, Erasmus D. Antiviral activity of biflavonoids isolated from the aerial parts of Hypericum perforatum. J Nat Prod 1993;56:137–47.

El-Abyad MS, Morsi NM, Zaki DA, Shaaban MT. Preliminary phytochemical investigation of two Egyptian medicinal plants. J Ethnopharmacol 1992;36:155–61.

Al-Abady MS, Morvi NM, Zaidi DA. Shabban MT. Preliminary biochemical screening of some Egyptian weeds for antimicrobial activity. Microbiol 1990;62:47–57.

Akladros AJ, Sotowa A, Leary JD. Preliminary biological and phytochemical investigation of two Nigerian medicinal plants. Int J Crude Drug Res 1986;24:38–42.

Mahmoud MI, Jowad AL, Hassan AM, Al-Masri M, Al-Niaj A. In vitro antiviral activity of Salvia rosmarinus and Allium sativum. Int J Crude Drug Res 1989;27:14–6.

Quareghq MV, Tersloch ML, Buenger MD, Abdiha LB. Antimicrobial activity of flavones from Anthemis cotula. Fitoterapia 2000;71:710–2.

Rauda JP, Remes S, Heinonen M, et al. Antimicrobial effects of Finnish plant extracts containing flavonoids and other phenolic compounds. Int J Food Microbiol 2000;56:3–12.

Singh RK, Nad G. Antimicrobial activity of Eclipta prostrata. Phytother Res 1995;9:448–50.

Tarle D, Dvoracek J. Antiviral activity of the plant Cirsium oleraceum (L.) Scop. Acta Pharrn J Hosp 1990;40:580–7.

Torrenegra RD, Ricardo AA, Pefaro OF. Flavonoids from Geophila gracile H.B.K. Int J Crude Drug Res 1989;27:14–6.

Park YK, Ikegaki M. Preparation of water and ethanolic extracts of propolis and evaluation of the preparations. BioSci Biotechnol Bioprod 1998;62:2230–2.

Khanna P, Sharma OP, Sengal M, et al. Antimicrobial principles from tissue culture of some plant species. Indian J Pharm Sci 1980;42:113–7.

Pomilio AB, Buschi CA, Tomes CN, Viale AA. Antimicrobial activity of pure flavonoids isolated from mosses. Phytochemistry 1999;52:679–82.

Bascle A, Sorbo S, Giordano S, et al. Antibacterial and antifungal activity of some flavones (1). Bioorg Med Chem Lett 1993;3:225–8.

Bashir AK, Abdalla AA, Wusti IA, Hassan ES, Amira MB, Cairo TA. Flavonoids of Zimonian avellanae. Int J Pharrmaco 1994;32:366–72.

Aljancic I, Vajs V, Menkovic N, et al. Flavones and sesquiterpene lactones from Arctium lappa. J Nat Prod 1990;54:97–82.

Dall'Agnol R, Ferraz A, Bernardi AP, et al. Antimicrobial activity of flavones and flavans. In: Cody V, Malidoni E, Harborne JB, editors. Plant flavonoids in biology and medicine: biochemical, pharmacological, and structure-activity relationships. New York, NY: Alan R. Liss, Inc.; 1986.

Aljancic I, Vajs V, Menkovic N, et al. Flavones and sesquiterpene lactones from Arctium lappa. J Nat Prod 1990;54:97–82.

Meyer JJ, Alfordyan AJ, Taylor MB, Erasmus D. Antiviral activity of galagan isolated from the aerial parts of Helichrysum aruostrum. J Ethnopharmacol 1993;56:165–9.

Amores M, Simoes CM, Girre L, Sauvager F, Cormier M. Synergistic effect of flavones and flavonoids against herpes simplex virus type 1 in cell culture. Comparison with the antiviral activity of propolis. J Nat Prod 1992;55:1732–40.

Mucio I, Goyal Z, B halla I. Combined effects of flavonoids and acyclovir against herpesvirus in cell cultures. Acta Microbiol Hung 1990;39:137–47.

Dall'Agnol R, Ferraz A, Bernardi AP, et al. Antimicrobial activity of some Hyssopus species. Phytomedicine 2000;71:301–16.

El-Alfy MS, Morvi NM, Zaidi DA. Shabban MT. Preliminary biological and phytochemical investigation of some Egyptian weeds for antimicrobial activity. Microbiol 1990;62:47–57.

Alkadros AJ, Sotowa A, Leary JD. Combined effects of flavonoids and acyclovir against herpesvirus in cell cultures. Acta Microbiol Hung 1990;39:137–47.

Dall'Agnol R, Ferraz A, Bernardi AP, et al. Antimicrobial activity of some Hyssopus species. Phytomedicine 2000;71:301–16.

El-Alfy MS, Morvi NM, Zaidi DA. Shabban MT. Preliminary biological and phytochemical investigation of some Egyptian weeds for antimicrobial activity. Microbiol 1990;62:47–57.

Alkadros AJ, Sotowa A, Leary JD. Combined effects of flavonoids and acyclovir against herpesvirus in cell cultures. Acta Microbiol Hung 1990;39:137–47.
[82] Cottiglia F, Loy G, Garan D, et al. Antimicrobial evaluation of compounds and edibles extracts from the stems of Daphne gnido L. Phytomedicine 2001;8:302–5.

[83] Sakagami Y, Mimura M, Kajimura K, et al. Anti-MRSA activity of flavonoids from Camellia sinensis. J Med Chem 1996;39:741–3.

[84] Alcazar LE, Blanco SE, Paig ON, Tomas F, Ferreth F. Antibacterial activity of flavonoids from Euphorbia marginata isolated from leaves against methicillin-resistant Staphylococcus aureus. J Med Chem 2000;43:572–4.

[85] Encarnacion R, Oshra N, Antonii U, Christophersen C, Nielsen PH. Two new flavonoids from Calluna vulgaris. J Nat Prod 1994;57:1307–9.

[86] Alcaraz LE, Blanco SE, Puig ON, Tomas F, Ferreth F. Antibacterial activity of flavonoids against Enterobacteriaceae. J Med Chem 1996;39:741–3.

[87] Encarnacion R, Oshra N, Antonii U, Christophersen C, Nielsen PH. Two new flavonoids from Calluna vulgaris. J Nat Prod 1994;57:1307–9.

[88] Bracken-Munday E, Rios J, HSP, et al. Inhibition of the growth of methicillin-resistant Staphylococcus aureus by catechins and gallates. Phytochemistry 2004;23:462–7.

[89] Bracken-Munday E, Rios J, HSP, et al. Inhibition of the growth of methicillin-resistant Staphylococcus aureus by catechins and gallates. Phytochemistry 2004;23:462–7.

[90] Seida T, Matsuyama T, Kusano H, et al. Inhibition of the growth of methicillin-resistant Staphylococcus aureus by catechins and gallates. Phytochemistry 2004;23:462–7.

[91] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[92] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[93] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[94] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[95] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[96] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[97] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[98] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[99] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[100] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[101] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[102] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[103] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[104] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[105] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[106] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[107] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[108] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[109] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[110] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[111] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[112] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[113] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[114] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[115] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[116] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[117] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[118] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[119] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[120] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.

[121] Ramaswamy AS, Jayaraman S, Sirsi M, Rao KH. Antibacterial activity of flavonoids from Helichrysum italicum L. J Nat Prod 1985;48:1353–8.
Arima H, Ashida H, Danno G. Rutin-enhanced antibacterial activities of flavonoids against Bacillus cereus and Salmonella enteritidis. Biosci Biotechnol Biochem 2002;66:1009–14.

Ayan-Kilcigil G, Bozdag O, Tuncbilek M, Altanlar N, Ertan R. Synthesis and antimicrobial activity of flavone-6-carboxaldehyde oxime ether derivatives. Pharmazie 1999;54:228–9.

Bordag-Dundar O, Tuncbilek M, Altanlar N, Ertan R. Synthesis and antimicrobial activity of flavone-3′-carboxaldehyde oxime ether derivatives. Arzneimittelforschung 2003;53:522–5.

Tuncbilek M, Bordag O, Ayan-Kilcigil G, Altanlar N, Buyukbingol E, Ertan R. Synthesis and antimicrobial activity of some new flavon oxime ether derivatives. Arzneimittelforschung 1999;49:853–7.

Wang SX, Zhang FJ, Feng QP, Li YL. Synthesis, characterization, and antibacterial activity of transition metal complexes with 5-hydroxy-7,4′-dimethoxyflavone. J Inorg Biochem 1992;46:251–7.

Ward FE, Garling DL, Buckler RT, Lawler DM, Cummings DP. Antimicrobial 3-methyleneflavanones. J Med Chem 1981;24:1073–7.

Vijaya K, Ananthan S. Therapeutic efficacy of medicinal plants against experimentally induced shigellosis in guinea pigs. Indian J Pharm Sci 1996;58:191–3.

Maier NK, Khalil AA, Nasri AA, al-Hin MM, Ali WM. Isolation of the antimicrobial alkaloid stemmadenine from Iraqi Rhazya stricta. J Nat Prod 1988;51:186–7.

Lin JS, Durham DG, Richards RME. Bacterial synergy with beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus and other beta-lactam-resistant strains of S. aureus. J Pharm Pharmacol 2000;52:361–6.

National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline (M26-A), Vol. 19 (18). Wayne, PA: NCCLS; 2000.

National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved guideline (M7-A5), Vol. 20 (2). Wayne, PA: NCCLS; 2000.

Haraguchi H, Tanimoto K, Tamura Y, Minatani K, Kinoshita T. Mode of antibacterial action of retrochalcones from Glycyrrhiza inflata. Phytochemistry 1998;48:125–9.

Mori A, Nishino C, Endo N, Tsuchiya H, Iinuma M. Reduction of membrane fluidity by antibacterial sophorahflavanone G isolated from Sophora scoparia. Phytomedicine 2000;7:161–4.

Sato M, Tsuchiya H, Akagiri M, Takagi N, Iinuma M. Growth inhibition of oral bacteria related to denture stomatitis by antifungal chalcones. Aust Dent J 1997;42:343–6.

Bilandji J, Krause HM, Bernstein RL, et al. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Adv Exp Med Biol 1995;390:59–69.

Hillard DJ, Krause HM, Bernstein RL, et al. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Adv Exp Med Biol 1995;390:59–69.

Plaper A, Golob M, Rafter I, Oblik M, Solmajer T, Jerala R. Characterization of quinol binding site on DNA gyrase. Biochem Biophys Res Commun 2003;306:536–8.

Bernard FX, Sable S, Cameron B, et al. Glycosylated flavones as selective inhibitors of topoisomerase IV. Antimicrob Agents Chemother 1997;41:992–8.

Normark S. Transduction and dominance studies of the emr gene present in a chain-forming mutant of Escherichia coli K12. J Gen Microbiol 1969;57.

Normark S, Boman HG, Matson E. Mutant of Escherichia coli with anomalous cell division and ability to decrease epimysially and chromosomally mediated resistance to ampicillin and several other antibiotics. J Bacteriol 1969;97:1334–42.

Cushnie TPT, Lamb AJ. Assessment of the antibacterial activity of galangin against 4-quinolone resistant strains of Staphylococcus aureus. Phytotherapy, in press.